-
Karyopharm Therapeutics (KPTI) Opportunity Seems Underappreciated Post Physician Checks - RBC Capital
-
Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
-
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
-
Karyopharm Therapeutics (KPTI) Prices 6.25M Share Common Offering at $24/Sh
-
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
-
Karyopharm Therapeutics (KPTI) PT Raised to $37 at RBC Capital
-
Karyopharm Therapeutics (KPTI) PT Raised to $22 at RBC Capital
-
Karyopharm to Participate in Upcoming Investor Conferences
-
Karyopharm to Participate in Upcoming Investor Conferences
-
Karyopharm Therapeutics (KPTI) PDUFA Delay Signals FDA Receptivity - RBC
-
Karyopharm Therapeutics (KPTI) PT Lowered to $16 at RBC Capital
-
RBC Still Sees Value for Karyopharm Therapeutics' (KPTI) Selinexor Albeit Delayed, PT To $17
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Pre-Open Movers 12/03: (TSRO) (GBT) (NBEV) Higher; (OCUL) (BLUE) (GSK) Lower (more...)
-
Buy Karyopharm (KPTI) Into ASH - RBC
-
RBC Capital Remains Buyers of Karyopharm Therapeutics (KPTI) Following 8% Gain
-
Karyopharm Therapeutics (KPTI) PT Lowered to $25 at RBC Capital, Remains Positive
-
Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'
-
Karyopharm to Participate in Upcoming Investor Conferences
-
Karyopharm to Participate in Upcoming Investor Conferences
-
RBC Capital Starts Karyopharm Therapeutics (KPTI) at Outperform
-
Notable Analyst Rating Changes 8/18: (PCLN) (KMI) (TOO) Upgraded; (TWTR) (HMSY) (MMP) Downgraded
-
Notable Analyst Rating Changes 6/28: (TRV) (OLN) (RIO) Upgraded; (DISH) (LB) (DD) Downgraded
-
Pre-Open Stock Movers 6/26: (QLTI) (UNXL) (IRM) Higher; (RDEN) (BBBY) (MLHR) Lower (more...)
-
Karyopharm Therapeutics to Present at Upcoming Healthcare Conferences in February